Rogowski MA (2013) AMPA Receptors as a Molecular Target in Epilepsy Therapy; Acta Neurol Scand Suppl. 2013; (197): 9-18.
Gardiner K, et al. (2016) Discovery of the First α‑Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antagonist Dependent upon Transmembrane AMPA Receptor Regulatory Protein (TARP) γ‑8; Med. Chem. 2016, 59, 4753-4768
Witkin JM, Kato A, Gleason SD, Gernert D, Ornstein P, Porter W, Reel J, and Gardinier KM (2015a) Anticonvulsant and improved side-effect potential of LY3130481: the first g8-selective transmembrane AMPA receptor regulatory protein (TARP) antagonist, in Proceedings of Neuroscience 2015; 2015 Oct 17-21; Chicago. Society for Neuroscience, Washington, DC.
Akihiko S Kato, Kevin D Burris, Kevin M Gardinier, Douglas L Gernert, Warren J Porter, Jon Reel, Chunjin Ding, Yuan Tu, Douglas A Schober, Matthew R Lee, Beverly A Heinz, Thomas E Fitch, Scott D Gleason, John T Catlow, Hong Yu, Stephen M Fitzjohn, Francesca Pasqui, He Wang, Yuewei Qian, Emanuele Sher, Ruud Zwart, Keith A Wafford, Kurt Rasmussen, Paul L Ornstein, John T R Isaac, Eric S Nisenbaum, David S Bredt, & Jeffrey M Witkin (2016) Forebrain-selective AMPA-receptor antagonism guided by TARP γ-8 as an antiepileptic mechanism, in Nature Medicine published online 7 November 2016; doi:10.1038/nm.4221
Disclaimer: These links are being provided as a convenience and for informational purposes only. The views, opinions and conclusions expressed in the links above are those of the authors and do not necessarily reflect the views, opinions and conclusions of the Company. The Company bears no responsibility for the accuracy, legality or content of any external links.